135080-35-2

Basic information

• Product Name: 1,3,4,5,6-penta-O-benzyl-2-deoxy-2-fluoro-myo-inositol
• CAS NO: 135080-35-2
• Molecular Weight: 632.772
• Mol File: 135080-35-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1,3,4,5,6-penta-O-benzyl-2-deoxy-2-fluoro-myo-inositol(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,4,5,6-penta-O-benzyl-2-deoxy-2-fluoro-myo-inositol(135080-35-2)
• EPA Substance Registry System: 1,3,4,5,6-penta-O-benzyl-2-deoxy-2-fluoro-myo-inositol(135080-35-2)

Safety Data

• Hazardous Substances Data: 135080-35-2(Hazardous Substances Data)

Upstream product

• 22132-86-1 meso-2,3,4,5,6-O-pentabenzyl-scyllo-inositol 
• 22144-57-6 meso-2,3,4,5,6-O-pentabenzyl-scyllo-ionose 
• 6195-45-5 meso-1,3,4,5,6-penta-O-benzyl-myo-inositol 
• 38078-09-0 diethylamino-sulfur trifluoride 
• 26276-99-3 rac-1,4,5,6-tetra-O-benzyl-myo-inositol 
• 135080-36-3 1,3,4,5,6-penta-O-benzyl-myo-inositol triflate 
• 135080-37-4 1,2,3,4,5-penta-O-benzyl-scyllo-inositol trifluoroacetate 
• 100-39-0 benzyl bromide 
• 28140-40-1 1,4,5,6-tetra-O-benzyl-myo-inositol 
• 100-44-7 benzyl chloride 
• 57029-87-5 (±)-1,2-cyclohexylidene myo-inositol 
• 87-89-8 D-myo-inositol 

Downstream Products

• 135212-48-5 2-deoxy-2-fluoro-myo-inositol 
• 85716-59-2 2-deoxy-2-fluoro-scyllo-inositol 

Relevant articles and documents

ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER

The present disclosure relates to pharmaceutical compositions including a compound derived from a parent compound having a hydroxyl or amino moiety, wherein the hydroxyl in the parent compound is presented as an ester in the compound or the amino in the parent compound is presented as an amide in the compound, and their use to prevent or treat neurological disease.

Synthesis of -Labelled and Unlabelled 2-Deoxy-2-fluoro-myo-inositol and 1-Deoxy-1-fluoro-scyllo-inositol for Use in Studies of the Phosphoinositide Cycle

2-Deoxy-2-fluoro-myo-inositol and 1-deoxy-1-fluoro-scyllo-inositol have been synthesized in their unlabelled and tritiated forms in order to study their potential as inhibitors of the phosphoinositide cycle.